المؤلفون: Wolf, Nadine

مصطلحات موضوعية: neuropathic pain, Chemotherapie-induzierte Polyneuropathie, diabetische Polyneuropathie, diabetic polyneuropathy, exercise therapy, quality of life, neuropathische Schmerzen, chemotherapy-induced polyneuropathy, CIPN, DPN, Trainingstherapie, Lebensqualität

وصف الملف: kein Volltext verfügbar

URL الوصول: https://explore.openaire.eu/search/publication?articleId=od_____10650::e16033d345be6a9b5e9aca5e26835efc

المؤلفون: Leefken, Henrike

مصطلحات موضوعية: Physiotherapie, EORTC QLQ-CIPN20, 6MWT, Onkologie, Bedarfsevaluation, Chemotherapie- induzierte Polyneuropathie, Leistungsfähigkeit

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::005fe47865dcc58529c3ded1898de939

المؤلفون: Steimann, Monika

المصدر: GMS Onkologische Rehabilitation und Sozialmedizin; VOL: 10; DOC03 /20210727/

مصطلحات موضوعية: sozialmedizinische Begutachtung, Chemotherapie-induzierte Polyneuropathie, ddc: 610, Therapie-induzierte Polyneuropathie, Medicine and health, socio-medical assessment, cancer, chemotherapy-induced polyneuropathy, maligne Erkrankungen, therapy-induced polyneuropathy

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::344db76a5081cb58f5801b915171cdeb
http://nbn-resolving.de/urn:nbn:de:0183-ors0000438

المؤلفون: Wolf, Nadine

مصطلحات موضوعية: neuropathische Schmerzen, Lebensqualität, Chemotherapie-induzierte Polyneuropathie, CIPN, diabetische Polyneuropathie, DPN, Trainingstherapie, neuropathic pain, quality of life, chemotherapy-induced polyneuropathy, diabetic polyneuropathy, exercise therapy

جغرافية الموضوع: FCW:GH:PT, vls-obvfcwoa-1303711

وصف الملف: kein Volltext verfügbar

Relation: vignette : https://pub.fh-campuswien.ac.at/titlepage/urn/urn:nbn:at:at-fhcw:1-96587/128; urn:nbn:at:at-fhcw:1-96587; https://resolver.obvsg.at/urn:nbn:at:at-fhcw:1-96587

الاتاحة: https://resolver.obvsg.at/urn:nbn:at:at-fhcw:1-96587

المؤلفون: Stocker, Franziska

مصطلحات موضوعية: Chemotherapie-induzierte Polyneuropathie, Interventionelle Bewegungstherapie, Polyneuropathies, Physical therapy modalities, Vibrationstraining, Bewegungstherapie, ddc:610, DDC 610 / Medicine & health

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3a7560d82a92407f6272f5a2e9a14ae

المؤلفون: Stocker, Franziska

الاتاحة: http://data.europeana.eu/aggregation/europeana/2048441/item_4U3MPQ4TDXMCNJHCZ5YNATCWSZOYR3DK

Additional Titles: Socio-medical significance of therapy-induced polyneuropathy in oncological patients

المؤلفون: Steimann, M

المصدر: GMS Onkologische Rehabilitation und Sozialmedizin; VOL: 10; DOC03 /20210727/

مصطلحات الفهرس: socio-medical assessment, cancer, therapy-induced polyneuropathy, chemotherapy-induced polyneuropathy, sozialmedizinische Begutachtung, maligne Erkrankungen, Chemotherapie-induzierte Polyneuropathie, Therapie-induzierte Polyneuropathie, ddc: 610, article

URL: http://nbn-resolving.de/urn:nbn:de:0183-ors0000438
http://www.egms.de/en/journals/ors/2021-10/ors000043.shtml
Ahn S, Song R. Effects of Tai Chi Exercise on glucose control, neuropathy scores, balance, and quality of life in patients with type 2 diabetes and neuropathy. J Altern Complement Med. 2012 Dec;18(12):1172-8. DOI: 10.1089/acm.2011.0690
André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, de Gramont A. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009 Jul 1;27(19):3109-16. DOI: 10.1200/JCO.2008.20.6771
Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris MG, Scher HI, Schrag D. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol. 2006 Nov;7(11):903-9. DOI: 10.1016/S1470-2045(06)70910-X
Bennett BK, Park SB, Lin CS, Friedlander ML, Kiernan MC, Goldstein D. Impact of oxaliplatin-induced neuropathy: a patient perspective. Support Care Cancer. 2012 Nov;20(11):2959-67. DOI: 10.1007/s00520-012-1428-5
Binda D, Vanhoutte EK, Cavaletti G, Cornblath DR, Postma TJ, Frigeni B, Alberti P, Bruna J, Velasco R, Argyriou AA, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galiè E, Briani C, Dalla Torre C, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey D, Kerrigan S, Schenone A, Fabbri S, Rossi E, Valsecchi MG, Faber CG, Merkies IS; CI-PeriNomS study group, Galimberti S, Lanzani F, Mattavelli L, Piatti ML, Bidoli P, Cazzaniga M, Cortinovis D, Lucchetta M, Campagnolo M, Bakkers M, Brouwer B, Boogerd W, Grant R, Reni L, Piras B, Pessino A, Padua L, Granata G, Leandri M, Ghignotti I, Plasmati R, Pastorelli F, Heimans JJ, Eurelings M, Meijer RJ, Grisold W, Lindeck Pozza E, Mazzeo A, Toscano A, Russo M, Tomasello C, Altavilla G, Penas Prado M, Dominguez Gonzalez C, Dorsey SG. Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS). Eur J Cancer. 2013 Sep;49(13):2910-8. DOI: 10.1016/j.ejca.2013.04.004
Boyette-Davis JA, Cata JP, Zhang H, Driver LC, Wendelschafer-Crabb G, Kennedy WR, Dougherty PM. Follow-up psychophysical studies in bortezomib-related chemoneuropathy patients. J Pain. 2011 Sep;12(9):1017-24. DOI: 10.1016/j.jpain.2011.04.008
Brouwers EE, Huitema AD, Boogerd W, Beijnen JH, Schellens JH. Persistent neuropathy after treatment with cisplatin and oxaliplatin. Acta Oncol. 2009;48(6):832-41. DOI: 10.1080/02841860902806609
Brydøy M, Oldenburg J, Klepp O, Bremnes RM, Wist EA, Wentzel-Larsen T, Hauge ER, Dahl O, Fosså SD. Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J Natl Cancer Inst. 2009 Dec 16;101(24):1682-95. DOI: 10.1093/jnci/djp413
Bundesministerium für Arbeit und Soziales, Hrsg. Versorgungsmedizin-Verordnung - VersMedV. Versorgungsmedizinische Grundsätze. Stand: Mai 2020. Bonn; 2020. Anlage zu Paragraf 2. Teil D. Merkzeichen. S. 125-9. Verfügbar unter: https://www.bmas.de/DE/Service/Publikationen/k710-anhaltspunkte-fuer-die-aerztliche-gutachtertaetigkeit.html
Bundesministerium für Arbeit und Soziales, Hrsg. Versorgungsmedizin-Verordnung - VersMedV. Versorgungsmedizinische Grundsätze. Stand: Mai 2020. Bonn; 2020. Anlage zu Paragraf 2. Teil B. GDS-Tabelle. S. 27-112. Verfügbar unter: https://www.bmas.de/DE/Service/Publikationen/k710-anhaltspunkte-fuer-die-aerztliche-gutachtertaetigkeit.html
Calhoun EA, Welshman EE, Chang CH, Lurain JR, Fishman DA, Hunt TL, Cella D. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer. 2003 Nov-Dec;13(6):741-8. DOI: 10.1111/j.1525-1438.2003.13603.x
Cavaletti G, Frigeni B, Lanzani F, Mattavelli L, Susani E, Alberti P, Cortinovis D, Bidoli P. Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer. 2010 Feb;46(3):479-94. DOI: 10.1016/j.ejca.2009.12.008
Cavaletti G, Bogliun G, Marzorati L, Zincone A, Piatti M, Colombo N, Parma G, Lissoni A, Fei F, Cundari S, Zanna C. Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology. 2003 Nov 11;61(9):1297-300. DOI: 10.1212/01.wnl.0000092015.03923.19
Cavaletti G, Cornblath DR, Merkies ISJ, Postma TJ, Rossi E, Frigeni B, Alberti P, Bruna J, Velasco R, Argyriou AA, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galiè E, Briani C, Dalla Torre C, Faber CG, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey D, Kerrigan S, Schenone A, Fabbri S, Valsecchi MG; CI-PeriNomS Group, Mazzeo A, Pace A, Pessino A, Schenone A, Toscano A, Argyriou AA, Brouwer B, Frigeni B, Piras B, Briani C, Dalla Torre C, Dominguez Gonzalez C, Faber CG, Tomasello C, Binda D, Brandsma D, Cortinovis D, Psimaras D, Ricard D, Storey D, Cornblath DR, Galiè E, Lindeck Pozza E, Rossi E, Vanhoutte EK, Lanzani F, Pastorelli F, Altavilla G, Cavaletti G, Granata G, Kalofonos HP, Ghignotti I, Merkies ISJ, Bruna J, Hense J, Heimans JJ, Mattavelli L, Padua L, Reni L, Bakkers M, Boogerd M, Campagnolo M, Cazzaniga M, Eurelings M, Leandri M, Lucchetta M, Penas Prado M, Russo M, Valsecchi MG, Piatti ML, Alberti P, Bidoli P, Grant R, Plasmati R, Velasco R, Lalisang RI, Meijer RJ, Fabbri S, Dorsey
Cornblath DR, Chaudhry V, Carter K, Lee D, Seysedadr M, Miernicki M, Joh T. Total neuropathy score: validation and reliability study. Neurology. 1999 Nov 10;53(8):1660-4. DOI: 10.1212/wnl.53.8.1660
Delforge M, Bladé J, Dimopoulos MA, Facon T, Kropff M, Ludwig H, Palumbo A, Van Damme P, San-Miguel JF, Sonneveld P. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol. 2010 Nov;11(11):1086-95. DOI: 10.1016/S1470-2045(10)70068-1
Frigeni B, Piatti M, Lanzani F, Alberti P, Villa P, Zanna C, Ceracchi M, Ildebrando M, Cavaletti G. Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale. J Peripher Nerv Syst. 2011 Sep;16(3):228-36. DOI: 10.1111/j.1529-8027.2011.00351.x
Gräcmann N, Albrecht M. Erkrankungen der neuromuskulären Peripherie. In: Bundesanstalt für Straßenwesen, Hrsg. Begutachtungsleitlinien zur Kraftfahreignung. Stand 31.12.2019. Bremen: Fachverlag NW in der Carl Ed. Schünemann KG; 2020. (Berichte der Bundesanstalt für Straßenwesen, Reihe M: Mensch und Sicherheit; 115). Verfügbar unter: https://bast.opus.hbz-nrw.de/frontdoor/index/index/docId/2330
Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol. 2006 Feb;33(1):15-49. DOI: 10.1053/j.seminoncol.2005.12.010
Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi CL; American Society of Clinical Oncology. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014 Jun 20;32(18):1941-67. DOI: 10.1200/JCO.2013.54.0914
Hershman DL, Weimer LH, Wang A, Kranwinkel G, Brafman L, Fuentes D, Awad D, Crew KD. Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat. 2011 Feb;125(3):767-74. DOI: 10.1007/s10549-010-1278-0
Hile ES, Fitzgerald GK, Studenski SA. Persistent mobility disability after neurotoxic chemotherapy. Phys Ther. 2010 Nov;90(11):1649-57. DOI: 10.2522/ptj.20090405
Ibrahim EY, Ehrlich BE. Prevention of chemotherapy-induced peripheral neuropathy: A review of recent findings. Crit Rev Oncol Hematol. 2020 Jan;145:102831. DOI: 10.1016/j.critrevonc.2019.102831
Kidwell KM, Yothers G, Ganz PA, Land SR, Ko CY, Cecchini RS, Kopec JA, Wolmark N. Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01. Cancer. 2012 Nov 15;118(22):5614-22. DOI: 10.1002/cncr.27593
Kim BJ, Park HR, Roh HJ, Jeong DS, Kim BS, Park KW, Cho SC, So YT, Oh SY, Kim SJ. Chemotherapy-related polyneuropathy may deteriorate quality of life in patients with B-cell lymphoma. Qual Life Res. 2010 Oct;19(8):1097-103. DOI: 10.1007/s11136-010-9670-0
Koeppen S. Tumortherapiebedingte Neuropathie. Onkologe. 2009;15:142-9. DOI: 10.1007/s00761-008-1550-7
König V. Onkologische Erkrankungen (Übersichtskapitel). In: Deutsche Rentenversicherung Bund, Hrsg. Sozialmedizinische Begutachtung für die gesetzliche Rentenversicherung. Berlin, Heidelberg: Springer; 2011. p. 217-58. DOI: 10.1007/978-3-642-10251-6_10
Kropff M, Baylon HG, Hillengass J, Robak T, Hajek R, Liebisch P, Goranov S, Hulin C, Bladé J, Caravita T, Avet-Loiseau H, Moehler TM, Pattou C, Lucy L, Kueenburg E, Glasmacher A, Zerbib R, Facon T. Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. Haematologica. 2012 May;97(5):784-91. DOI: 10.3324/haematol.2011.044271
Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve. 2004 Mar;29(3):387-92. DOI: 10.1002/mus.10559
Moser EC, Noordijk EM, Carde P, Tirelli U, Baars JW, Thomas J, Bron D, Meerwaldt JH, van Glabbeke M, Raemaekers JM, Kluin-Nelemans HC. Late non-neoplastic events in patients with aggressive non-Hodgkin's lymphoma in four randomized European Organisation for Research and Treatment of Cancer trials. Clin Lymphoma Myeloma. 2005 Sep;6(2):122-30. DOI: 10.3816/CLM.2005.n.038
Pace A, Nisticò C, Cuppone F, Bria E, Galiè E, Graziano G, Natoli G, Sperduti I, Jandolo B, Calabretta F, Tomao S, Terzoli E. Peripheral neurotoxicity of weekly paclitaxel chemotherapy: a schedule or a dose issue? Clin Breast Cancer. 2007 Apr;7(7):550-4. DOI: 10.3816/CBC.2007.n.010
Park SB, Goldstein D, Krishnan AV, Lin CS, Friedlander ML, Cassidy J, Koltzenburg M, Kiernan MC. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin. 2013 Nov-Dec;63(6):419-37. DOI: 10.3322/caac.21204
Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, Hoang-Xuan K, Lantéri-Minet M, Grant R, Huddart R, Moynihan C, Maher J, Lucey R; EORTC Quality of Life Group. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer. 2005 May;41(8):1135-9. DOI: 10.1016/j.ejca.2005.02.012
Richardson PG, Xie W, Mitsiades C, Chanan-Khan AA, Lonial S, Hassoun H, Avigan DE, Oaklander AL, Kuter DJ, Wen PY, Kesari S, Briemberg HR, Schlossman RL, Munshi NC, Heffner LT, Doss D, Esseltine DL, Weller E, Anderson KC, Amato AA. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol. 2009 Jul 20;27(21):3518-25. DOI: 10.1200/JCO.2008.18.3087
Richardson PG, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Bladé J, Boccadoro M, Cavenagh JD, Boral AL, Esseltine DL, Wen PY, Amato AA, Anderson KC, San Miguel J. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol. 2009 Mar;144(6):895-903. DOI: 10.1111/j.1365-2141.2008.07573.x
Schubert W, Schneider W, Eisenmenger W, Stephan E. Begutachtungs-Leitlinien zur Kraftfahreignung. 2. Aufl. Bonn: Kirschbaum Verlag; 2005. p. 115-6.
Smith EM, Cohen JA, Pett MA, Beck SL. The reliability and validity of a modified total neuropathy score-reduced and neuropathic pain severity items when used to measure chemotherapy-induced peripheral neuropathy in patients receiving taxanes and platinums. Cancer Nurs. 2010 May-Jun;33(3):173-83. DOI: 10.1097/NCC.0b013e3181c989a3
Steimann M. Chemotherapieinduzierte Polyneuropathie: Grundlagen, Diagnostik und Prävention. GMS Onkol Rehabil Sozialmed. 2014;3:Doc05. DOI: 10.3205/ors000013
Steimann M, Kerschgens C, Barth J. Rehabilitation bei chemotherapieinduzierter Polyneuropathie. Onkologe. 2011;17:940. DOI: 10.1007/s00761-011-2111-z
Steurer M, Spizzo G, Mitterer M, Gastl G. Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program. Onkologie. 2004 Apr;27(2):150-4. DOI: 10.1159/000076904
Streckmann F, Zopf EM, Lehmann HC, May K, Rizza J, Zimmer P, Gollhofer A, Bloch W, Baumann FT. Exercise intervention studies in patients with peripheral neuropathy: a systematic review. Sports Med. 2014 Sep;44(9):1289-304. DOI: 10.1007/s40279-014-0207-5
Streckmann F, Hess V, Bloch W, Décard BF, Ritzmann R, Lehmann HC, Balke M, Koliamitra C, Oschwald V, Elter T, Zahner L, Donath L, Roth R, Faude O. Individually tailored whole-body vibration training to reduce symptoms of chemotherapy-induced peripheral neuropathy: study protocol of a randomised controlled trial-VANISH. BMJ Open. 2019 Apr 24;9(4):e024467. DOI: 10.1136/bmjopen-2018-024467
Streckmann F, Kleber M, Gollhofer A, Kneis S, Bertz H, Leifert JA. Sensorimotor Training has a positive influence on Patients with Malignant Lymphoma Receiving Chemotherapy. Onkologie. 2011;34(Suppl. 6):46-8.
Strumberg D, Brügge S, Korn MW, Koeppen S, Ranft J, Scheiber G, Reiners C, Möckel C, Seeber S, Scheulen ME. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol. 2002 Feb;13(2):229-36. DOI: 10.1093/annonc/mdf058
U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE v5.0). National Cancer Institute; 2017. Verfügbar unter: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf
Urban P. Klinisch-neurologische Untersuchungstechniken. 2. überarb. Aufl. Stuttgart: Georg Thieme Verlag; 2016. DOI: 10.1055/b-004-129680
Verstappen CC, Koeppen S, Heimans JJ, Huijgens PC, Scheulen ME, Strumberg D, Kiburg B, Postma TJ. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology. 2005 Mar 22;64(6):1076-7. DOI: 10.1212/01.WNL.0000154642.45474.28
Vogt T, Körber J, Barth J, Ingel K; Neurologische Klinik der Universität Mainz; Klinik Nahetal Fachklinik für onkologische Nachsorge und Anschlussrehabilitation; Klinik Nordfriesland Fachklinik für onkologische Nachsorge und Anschlussrehabilitation. Klinische Relevanz und Therapie von therapieassoziierten Polyneuropathien bei Patienten mit Tumor-Erkrankung. Abschlussbericht. Arbeitsgemeinschaft für Krebsbekämpfung der Träger der gesetzlichen Kranken- und Rentenversicherung im Lande Nordrhein-Westfalen; 2010. Verfügbar unter: https://www.argekrebsnw.de/wp-content/uploads/PNP-Studie-Endfassung.pdf
Zara G, Ermani M, Rondinone R, Arienti S, Doria A. Thalidomide and sensory neurotoxicity: a neurophysiological study. J Neurol Neurosurg Psychiatry. 2008 Nov;79(11):1258-61. DOI: 10.1136/jnnp.2008.147892